AGIO Historical PE Ratio image   This AGIO PE ratio history page last updated 11/7/2022
AGIO Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/3/2022
26.36-1.49-5.96NA
Q2 2022
8/4/2022
28.61-1.68-6.72NA
Q1 2022
5/5/2022
23.00-1.74-6.96NA
Q4 2021
2/24/2022
29.13-1.74-6.96NA
Q3 2021
11/3/2021
49.64-1.56-6.24NA
Q2 2021
7/29/2021
49.84-1.44-5.76NA
Q1 2021
4/29/2021
55.78-1.31-5.24NA
Q4 2020
2/25/2021
50.29-1.41-5.64NA
Q3 2020
11/5/2020
42.08-1.43-5.72NA
Q2 2020
7/30/2020
47.45-1.31-5.24NA
Q1 2020
4/30/2020
41.14-0.59-2.36NA
Q4 2019
2/13/2020
52.01-1.60-6.40NA
Q3 2019
10/31/2019
30.08-1.81-7.24NA
Q2 2019
8/1/2019
42.74-1.87-7.48NA
Q1 2019
5/2/2019
51.50-1.59-6.36NA
Q4 2018
2/14/2019
57.42-1.58-6.32NA
Q3 2018
11/1/2018
68.51-1.63-6.52NA
Q2 2018
8/2/2018
80.41-1.19-4.76NA
Q1 2018
5/4/2018
80.68-1.63-6.52NA
Q4 2017
2/14/2018
77.97-1.81-7.24NA
Q3 2017
11/1/2017
62.01-1.59-6.36NA
Q2 2017
8/8/2017
59.51-1.78-7.12NA
Q1 2017
5/4/2017
47.27-1.56-6.24NA
Q4 2016
2/16/2017
49.83-1.34-5.36NA
Q3 2016
11/3/2016
47.63-1.63-6.52NA
Q2 2016
8/4/2016
43.72-1.47-5.88NA
Q1 2016
5/4/2016
44.16-0.61-2.44NA
Q4 2015
2/18/2016
37.15-1.08-4.32NA
Q3 2015
11/5/2015
75.25-1.07-4.28NA
Q2 2015
8/6/2015
100.05-0.85-3.40NA
Q1 2015
5/7/2015
99.13-0.13-0.52NA
Q4 2014
2/17/2015
108.41-0.76-3.04NA
Q3 2014
11/7/2014
72.060.100.40180.2
Q2 2014
8/7/2014
37.10-0.54-2.16NA
Q1 2014
5/8/2014
36.79-0.39-1.56NA
Q4 2013
3/6/2014
39.93-0.40-1.60NA
Q3 2013
9/30/2013
27.963.0112.042.3
Q2 2013
6/30/2013
NA-2.80-11.20NA
Q1 2013
3/31/2013
NA-2.47-9.88NA
AGIO PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/3/2022
26.36-1.49-6.65NA
Q2 2022
8/4/2022
28.61-1.68-6.72NA
Q1 2022
5/5/2022
23.00-1.74-6.48NA
Q4 2021
2/24/2022
29.13-1.74-6.05NA
Q3 2021
11/3/2021
49.64-1.56-5.72NA
Q2 2021
7/29/2021
49.84-1.44-5.59NA
Q1 2021
4/29/2021
55.78-1.31-5.46NA
Q4 2020
2/25/2021
50.29-1.41-4.74NA
Q3 2020
11/5/2020
42.08-1.43-4.93NA
Q2 2020
7/30/2020
47.45-1.31-5.31NA
Q1 2020
4/30/2020
41.14-0.59-5.87NA
Q4 2019
2/13/2020
52.01-1.60-6.87NA
Q3 2019
10/31/2019
30.08-1.81-6.85NA
Q2 2019
8/1/2019
42.74-1.87-6.67NA
Q1 2019
5/2/2019
51.50-1.59-5.99NA
Q4 2018
2/14/2019
57.42-1.58-6.03NA
Q3 2018
11/1/2018
68.51-1.63-6.26NA
Q2 2018
8/2/2018
80.41-1.19-6.22NA
Q1 2018
5/4/2018
80.68-1.63-6.81NA
Q4 2017
2/14/2018
77.97-1.81-6.74NA
Q3 2017
11/1/2017
62.01-1.59-6.27NA
Q2 2017
8/8/2017
59.51-1.78-6.31NA
Q1 2017
5/4/2017
47.27-1.56-6.00NA
Q4 2016
2/16/2017
49.83-1.34-5.05NA
Q3 2016
11/3/2016
47.63-1.63-4.79NA
Q2 2016
8/4/2016
43.72-1.47-4.23NA
Q1 2016
5/4/2016
44.16-0.61-3.61NA
Q4 2015
2/18/2016
37.15-1.08-3.13NA
Q3 2015
11/5/2015
75.25-1.07-2.81NA
Q2 2015
8/6/2015
100.05-0.85-1.64NA
Q1 2015
5/7/2015
99.13-0.13-1.33NA
Q4 2014
2/17/2015
108.41-0.76-1.59NA
Q3 2014
11/7/2014
72.060.10-1.23NA
Q2 2014
8/7/2014
37.10-0.541.6822.1
Q1 2014
5/8/2014
36.79-0.39-0.58NA
Q4 2013
3/6/2014
39.93-0.40-2.66NA
Q3 2013
9/30/2013
27.963.01NANA
Q2 2013
6/30/2013
NA-2.80NANA
Q1 2013
3/31/2013
NA-2.47NANA
Quotes delayed 20 minutes

Email EnvelopeFree AGIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Agios Pharmaceuticals (AGIO) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

AGL PE Ratio History
AGLE PE Ratio History
AGRX PE Ratio History
AGTC PE Ratio History
AGTI PE Ratio History
AHCO PE Ratio History
AHPI PE Ratio History
AIKI PE Ratio History
AKBA PE Ratio History
AKRO PE Ratio History
How should the AGIO historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Agios Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this AGIO Historical PE Ratio page.

What is the average historical PE for AGIO based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The AGIO historical PE ratio using the annualized quarterly earnings method works out to 91.2.

What is the average historical PE for AGIO based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The AGIO historical PE ratio using the TTM earnings method works out to 22.1.

On this page we presented the AGIO Historical PE Ratio information for Agios Pharmaceuticals' stock. The average AGIO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 91.2. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average AGIO historical PE based on this TTM earnings result method is 22.1. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this AGIO historical PE result, against the recent PE: when this page was posted on 11/4/2022, the most recent closing price for AGIO had been 25.90, and the most recent quarterly earnings result, annualized, was 0.4. Meanwhile, the most recent TTM earnings summed to 1.68. From these numbers, we calculate the recent AGIO PE on 11/4/2022 based on annualized quarterly EPS was 64.7. Based on AGIO's history, that recent PE is low relative to the historical average, with the recent PE 29.1% lower than the historical average PE across our data set for Agios Pharmaceuticals. Looking at the recent AGIO PE on 11/4/2022 based on TTM EPS, we calculate the ratio at 15.4. Based on AGIO's history, that recent PE is low relative to the historical average, with the recent PE 30.3% lower than the average PE across our Agios Pharmaceuticals data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on AGIO or any other given stock, valuation analysis for AGIO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Agios Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for AGIO. Thanks for visiting, and the next time you need to research AGIO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: PCB YTD Return, VM Videos, SOR Videos.

 

AGIO Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.